Fetal valproate syndrome
Other Names for this Disease
- Embryofoetal valproic acid syndrome
- Valproic acid embryopathy
- Valproic acid fetal effects from
RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.
Third Conference of the MENA Initiative: Future Directions in Developmental Disabilities: Prevention, Screening, and Treatment, Tuesday, April 27, 2010 - Thursday, April 29, 2010
Location: Doha, Qatar
Description: The goals of the meeting were to enhance prevention, screening, and treatment of developmental disabilities in the Middle East and North Africa (MENA) and to develop partnerships for building regional resources that will support patient treatment and research collaboration. This included expanding the conditions that had been addressed in the previous conferences to include neurosensory and neurodevelopmental conditions in addition to metabolic conditions.
VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.